Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024. In the quarter to June 2026, revenue fell 8.33%, EPS fell 15.4% and free cash flow fell 98.8%, each against the same quarter a year earlier.
Follow ACRS
Aclaris Therapeutics, Inc. (ACRS) P/E ratio
Aclaris Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 32 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CTMX CytomX Therapeutics, Inc. compare | n/m |
| MNPR Monopar Therapeutics Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| VECT VectivBio Holding AG compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| ACRS Aclaris Therapeutics, Inc. | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 18.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)